HOLD CRM
0 shares at $202.60 on 2026-03-03
Reasoning
SKIP this action. CRM is up +2.6% today and consolidating within thesis 94 entry zone ($185-205). However, with only $215 buying power remaining and multiple higher-priority actions (AVGO trim, ABNB exit, XLE add), deploying $40 to CRM now is excessive capital allocation. The 'watch-first' thesis validation is noted, but we should wait for ABNB proceeds (~$74.5) to settle before new tech additions. Confidence level (0.5) and lower priority (3) warrant deferral. CRM will remain on watch list for add-on after portfolio rebalancing completes.
Thesis
CRM is showing signs of bottoming. Stock surged +4.7% today to $202.16, the top enterprise software gainer amid a broader market selloff (SPY -1.18%). This is the best single-day performance since earnings. The "SaaSpocalypse" narrative may be exhausting itself. Agentforce ARR $800M (+169% YoY), $50B buyback, and FY2026 revenue of $41.53B (+9.58%) provide fundamental support. Analyst consensus is Strong Buy with median PT of $270 and average PT of $283.44. CRM is now trading within our $185-205 entry zone. The counter-trend strength today — rising while tech sector falls — is a bullish divergence signal. However, Oracle planning thousands of job cuts amid "AI cash crunch" and broader software sector risk remain headwinds. (long, medium confidence)
Cited evidence
Theses